01 September 1997
Long-term monitoring of an immune response to tumor and LDH viral antigen in patients with carcinoma of otorhinolaryngologic origin
Ales Cocek, Ales Hahn, Anna Jandova, Martina Nedbalova, Alena DohnalovaMed Sci Monit 1997; 3(5): CR657-660 :: ID: 501563
Abstract
Repeatedly over the course of 3 years, the authors studied the state of cell-mediated immunity (CMI) by means of an antigen prepared from the serum of C3H/H2K strain inbred mice infected by the LDH virus in 74 patients with a malignant tumor in the area of the head or neck who were treated in the Otolaryngology Clinic of the 3rd Medical Faculty, Charles Universtiy, Prague. The immune response to the LDH virus was determined by the leukocyte adherence inhibition test (LAI test) and the evaluation was carried out by means of an index of positivity (IP). The aim of the Study was to: a. ascertain whether the mean index of positivity at a moment of capture exceeds 1.3 in patients with malignant tumors of the head and neck, which is the standard obtained by examination of healthy people (blood donors), and whether it exceeds that in patients with precancer of the area studied; b. ascertain whether values of the index of positivity mutually differ in malignancies of particular localizations; c. ascertain whether and how the index of positivity changes in time, i.e. whether or not it is an indicator of successfulness of the treatment; It has been determined that the IP values in patients with malignant tumors of the head and neck differ from those obtained by the exaination of healthy people and patients with precancers of the area studied. IP values of malignant tumors with particular localizations do not differ from one another significantly. It must be admitted that IP values change in the course of treatment, however, the changes are being affected by many circumstances and particular cases must be approached individually.
Keywords: LDH virus RNA, malignant tumors of the head and neck, marker of the disease
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952